About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker RDY · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Aug 4, 2026A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants
NCT07744828 · Healthy Volunteers
DRL_AB
RDY
Dr. Reddy's Laboratories Limited
Phase 1Not yet recruiting160Dec 29, 2026Registry ↗
Jan 22, 2024Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabTher…
NCT03976102 · Follicular Lymphoma
DRL_RI (Proposed rituximab biosimilar), MabThera®
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed317Sep 28, 2022Registry ↗
Nov 18, 2023A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
NCT04268771 · Rheumatoid Arthritis
Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed140Jan 26, 2022Registry ↗
Nov 13, 2023Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by…
NCT06126042 · Rheumatoid Arthritis
Test Product, Reference product
RDY
Dr. Reddy's Laboratories Limited
Phase 1Unknown330Apr 2024Registry ↗
Apr 12, 2022A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Pl…
NCT02173301 · Psoriasis
XP23829 400 mg QD, XP 23829 800 mg QD
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed200May 2015Registry ↗
Apr 1, 2022A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
NCT03421197 · Psoriasis
PPC-06 400 mg QD, PPC-06 400 mg BID
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed426Mar 30, 2020Registry ↗
Mar 21, 2022Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Pat…
NCT04529499 · Covid19
AVIGAN, Placebo Comparator
RDY
Dr. Reddy's Laboratories Limited
Phase 3Terminated353Jan 22, 2021Registry ↗
Jul 26, 2021Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
NCT02061813 · Head Lice
Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed40Jan 2014Registry ↗
Jul 9, 2021Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
NCT01518699 · Pediculosis
Ha44, Ha44 Placebo
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed57May 2012Registry ↗
Jun 2, 2021Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Sev…
NCT04640233 · COVID-19 Prevention
Gam-COVID-Vac, Placebo
RDY
Dr. Reddy's Laboratories Limited
Phase 2/3Unknown1,600Aug 2021Registry ↗
May 11, 2021Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice…
NCT02097485 · Head Lice Infestation
Abametapir Lotion 0.74% w/w, Vehicle Lotion
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed50Sep 2014Registry ↗
Mar 1, 2021A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
NCT03599193 · Acne Vulgaris
Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1%
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed58Apr 30, 2018Registry ↗
Mar 1, 2021A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release…
NCT03340961 · Rosacea
DFD-29 Extended Release Capsules (40 mg), DFD-29 Extended R…
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed205Nov 7, 2018Registry ↗
Mar 1, 2021A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
NCT03292640 · Acne Vulgaris
DFD-03 (0.1% tazarotene) Lotion, DFD-03 (0% tazarotene) Lot…
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed547May 14, 2018Registry ↗
Mar 1, 2021A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
NCT03290027 · Acne Vulgaris
DFD-03, Placebo Comparator
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed550Apr 19, 2018Registry ↗
Jan 22, 2021Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15
NCT03554772 · Acute Pain
DFN-15 (Celecoxib Oral Solution) 62.5 mg, DFN-15 (Celecoxib…
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed120Aug 20, 2018Registry ↗
Sep 23, 2020A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice…
NCT02060903 · Head Lice Infestation
Abametapir Lotion 0.74% w/w, Vehicle Lotion
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed379Jul 2014Registry ↗
Aug 17, 2020A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to…
NCT03341910 · Acne Vulgaris
DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed155May 18, 2018Registry ↗
May 12, 2020Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice I…
NCT02062060 · Head Lice Infestation
Abametapir Lotion 0.74% w/w, Vehicle Lotion
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed325Jul 2014Registry ↗
May 12, 2020A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of H…
NCT02010333 · Head Lice Infestation
Ha44 Gel 0.74% w/w
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed22Jul 2014Registry ↗
Apr 29, 2020Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion
NCT02062073 · Head Lice
Abametapir Lotion 0.74% w/w, 0.1% sodium lauryl sulfate
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed238Mar 2014Registry ↗
Apr 29, 2020An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infe…
NCT01336647 · Pediculosis
Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44…
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed142Aug 2011Registry ↗
Apr 28, 2020Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation
NCT01907490 · Head Lice Infestation
Ha44 Gel
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed38Jul 2013Registry ↗
Jan 13, 2020Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclon…
NCT02296775 · Rheumatoid Arthritis
DRL_RI, Rituxan
RDY
Dr. Reddy's Laboratories Limited
Phase 1/2Completed276Nov 2016Registry ↗
Dec 16, 2019Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
NCT02301962 · Cancer
Panitumumab
RDY
Dr. Reddy's Laboratories Limited
Phase 4Unknown58Jun 30, 2021Registry ↗
Apr 24, 2019A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of…
NCT03116698 · Actinic Keratosis (AK)
Low dose DFD07 once daily, High dose DFD07 once daily
RDY
Dr. Reddy's Laboratories Limited
Phase 2/3Completed240Nov 13, 2017Registry ↗
Feb 26, 2019Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine
NCT02571049 · Rapidly Escalating Migraine
DFN-11
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed24Apr 2016Registry ↗
Jan 23, 2019A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
NCT02828241 · Rosacea
DFD-04 Ointment, Placebo Ointment
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed61Jan 2017Registry ↗
Oct 18, 2018Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions
NCT03696329 · Healthy
Tetrabenazine Tablets 25 mg
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed48Nov 2015Registry ↗
Oct 15, 2018Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200…
NCT03706300 · Healthy
Guaifenesin and Pseudoephedrine Hydrochloride Extended Rele…
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed80Jan 2015Registry ↗
Oct 11, 2018Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions
NCT03702855 · Healthy
Tetrabenazine Tablets 25 mg
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed48Dec 2015Registry ↗
Jul 26, 2018DFN-11 Injection in Episodic Migraine With or Without Aura
NCT02569853 · Episodic Migraine
DFN-11, Placebo
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed268May 30, 2017Registry ↗
May 22, 2018Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches
NCT02472418 · Migraine
DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B)
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed63Dec 1, 2015Registry ↗
Apr 3, 2018Pilot Study of DFN-11 Injection in Medication Overuse Headache
NCT02583425 · Medication Overuse Headache
DFN-11 Injection
RDY
Dr. Reddy's Laboratories Limited
Phase 2Terminated27Aug 2016Registry ↗
Mar 9, 2018DFN-02 Open Label Safety Study in Patients With Acute Migraine
NCT02279082 · Acute Migraine
DFN-02
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed167Sep 2015Registry ↗
Feb 13, 2018Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy…
NCT03282838 · Migraine
DFN-15 (fasted), DFN-15 (fed)
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed24Aug 22, 2017Registry ↗
Feb 13, 2018Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality…
NCT03051685 · Healthy
DFN-15 Dose 1, DFN-15 Dose 2
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed16Aug 14, 2015Registry ↗
May 19, 2017Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections
NCT03160807 · Urinary Tract Infection
Levofloxacin, Levofloxacin
RDY
Dr. Reddy's Laboratories Limited
Phase 4Unknown214Mar 2018Registry ↗
Mar 13, 2017Ketorol Gel in Gonarthrosis and Low Back Pain
NCT02638831 · Gonarthrosis, Low Back Pain
Ketorolac Tromethamine, Ketoprofen
RDY
Dr. Reddy's Laboratories Limited
Phase 4Completed240Nov 2013Registry ↗
Oct 14, 2016A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the T…
NCT02572986 · Scabies
Permethrin
RDY
Dr. Reddy's Laboratories Limited
Phase 3Completed250Jun 2016Registry ↗
Oct 11, 2016Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal S…
NCT01888367 · Surgical Site Infections
DFA-02 Antibiotic Gel, DFA-02 Placebo Gel
RDY
Dr. Reddy's Laboratories Limited
Phase 2Completed445Feb 2015Registry ↗
Oct 4, 2016Evaluation of the Efficacy and Safety of Nise 100 mg in the Management of Osteoarthrosis (Gonarthro…
NCT02922712 · Knee Osteoarthritis
NISE
RDY
Dr. Reddy's Laboratories Limited
Phase 4Completed202Jun 2013Registry ↗
Oct 4, 2016Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases
NCT02922699 · GERD
OMEZ 40, OMEZ 80
RDY
Dr. Reddy's Laboratories Limited
Phase 4Completed120Jun 2013Registry ↗
Sep 30, 2016Amtolmetin Gaucil in Knee Osteoarthritis
NCT02865161 · Knee Osteoarthritis
NISELAT
RDY
Dr. Reddy's Laboratories Limited
—Completed220Dec 2015Registry ↗
Sep 23, 2016Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection
NCT02260544 · Ovarian Epithelial Cancer Recurrent
Doxorubicin Hydrochloride Liposome Injection
RDY
Dr. Reddy's Laboratories Limited
Phase 1Completed49Apr 2015Registry ↗
Aug 16, 2016Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts
NCT02798419 · Common Warts
DFD05 Cream, Active01 Cream
RDY
Dr. Reddys Laboratories, SA
Phase 2Completed50May 2016Registry ↗
Mar 18, 2016Levofloxacin in Bacterial Rhinosinussitis
NCT02712502 · Rhinosinusitis
Levofloxacin, Amoxicillin-Potassium Clavulanate Combination
RDY
Dr. Reddy's Laboratories Limited
—Completed100Dec 2014Registry ↗
Mar 17, 2016Non Interventional Study of Levofloxacin in Chronic Prostatitis
NCT02711943 · Chronic Prostatitis
Levofloxacin 500
RDY
Dr. Reddy's Laboratories Limited
—Completed500Feb 2014Registry ↗

48 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:10 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances